Body weight cutoff for daily dosage of efavirenz and 60-week efficacy of efavirenz-based regimen in human immunodeficiency virus and tuberculosis coinfected patients receiving rifampin

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 10, 2009, Pages 4545-4548

  Manosuthi, Weerawat ^a,b,d   Sungkanuparph, Somnuek ^b   Tantanathip, Preecha ^b   Mankatitham, Wiroj ^b   Lueangniyomkul, Aroon ^b   Thongyen, Supeda ^b   Eampokarap, Boonchuay ^b   Uttayamakul, Sumonmal ^b   Suwanvattana, Pawita ^b   Kaewsaard, Samroui ^b   Ruxrungtham, Kiat ^c  

^a MINISTRY OF PUBLIC HEALTH   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

^c THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^d Bamrasnaradura Infectious Diseases Institute   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; EFAVIRENZ; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY; LAMIVUDINE; RIFAMPICIN; STAVUDINE; VIRUS RNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BEDTIME DOSAGE; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; RNA VIRUS; SKIN MANIFESTATION; TREATMENT DURATION; TUBERCULOSIS;

ANTI-HIV AGENTS; ANTIBIOTICS, ANTITUBERCULAR; BENZOXAZINES; BODY WEIGHT; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HUMANS; MALE; MULTIVARIATE ANALYSIS; RIFAMPIN; TUBERCULOSIS;

EID: 70349313476     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00492-09     Document Type: Article

References (17)

1. Brennan-Benson, P., R. Lyus, T. Harrison, M. Pakianathan, and D. Macallan. 2005. Pharmacokinetic interactions between efavirenz and rifampicin in the treatment of HIV and tuberculosis: one size does not fit all. AIDS 19:1541-1543. (Pubitemid 41400701)
2. Friedland, G., S. Khoo, C. Jack, and U. Lalloo. 2006. Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV. J. Antimicrob. Chemother. 58:1299-1302.
3. González de Requena, D., O. Gallego, A. Corral, I. Jimenez-Nacher, and V. Soriano. 2004. Higher efavirenz concentrations determine the response to viruses carrying non-nucleoside reverse transcriptase resistance mutations. AIDS 18:2091-2094.
4. Haas, D. W., H. J. Ribaudo, R. B. Kim, C. Tierney, G. R. Wilkinson, R. M. Gulick, D. B. Clifford, T. Hulgan, C. Marzolini, and E. P. Acosta. 2004. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 18:2391-2400.
5. Hollanders, R. M., E. W. van Ewijk-Beneken Kolmer, D. M. Burger, E. W. Wuis, P. P. Koopmans, and Y. A. Hekster. 2000. Determination of nevirapine, an HIV-1 non-nucleoside reverse transcriptase inhibitor, in human plasma by reversed-phase high-performance liquid chromatography. J. Chromatogr. B Biomed. Sci. Appl. 744:65-71.
6. Lopéz-Cortés, L. F., R. Ruiz-Valderas, P. Viciana, A. Alarcon-Gonzalez, J. Gomez-Mateos, E. Leon-Jimenez, M. Sarasanacenta, Y. Lopez-Pua, and J. Pachon. 2002. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. Clin. Pharmacokinet. 41:681-690.
7. Manosuthi, W., S. Kiertiburanakul, S. Sungkanuparph, K. Ruxrungtham, A. Vibhagool, S. Rattanasiri, and A. Thakkinstian. 2006. Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results. AIDS 20:131-132. (Pubitemid 41818129)
8. Manosuthi, W., W. Mankatitham, A. Lueangniyomkul, S. Chimsuntorn, and S. Sungkanuparph. 2008. Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin. HIV Med. 9:294-299.
9. Manosuthi, W., S. Sungkanuparph, P. Tantanathip, A. Lueangniyomkul, W. Mankatitham, W. Prasithsirskul, S. Burapatarawong, S. Thongyen, S. Likanonsakul, U. Thawornwa, V. Prommool, and K. Ruxrungtham. 2009. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study. Clin. Infect. Dis. 48:1752-1759.
10. Manosuthi, W., S. Sungkanuparph, A. Thakkinstian, A. Vibhagool, S. Kiertiburanakul, S. Rattanasiri, W. Prasithsirikul, J. Sankote, A. Mahanontharit, and K. Ruxrungtham. 2005. Efavirenz levels and 24-week efficacy in HIV-infected patients with tuberculosis receiving highly active antiretroviral therapy and rifampicin. AIDS 19:1481-1486. (Pubitemid 41400693)
11. Marzolini, C., A. Telenti, L. A. Decosterd, G. Greub, J. Biollaz, and T. Buclin. 2001. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 15:71-75. (Pubitemid 32055781)
12. Matteelli, A., M. Regazzi, P. Villani, G. De Iaco, M. Cusato, A. C. Carvalho, S. Caligaris, L. Tomasoni, M. Manfrin, S. Capone, and G. Carosi. 2007. Multiple-dose pharmacokinetics of efavirenz with and without the use of rifampicin in HIV-positive patients. Curr. HIV Res. 5:349-353.
13. Ramachandran, G., A. K. Hemanth Kumar, S. Rajasekaran, P. Kumar, K. Ramesh, S. Anitha, G. Narendran, P. Menon, C. Gomathi, and S. Swaminathan. 2009. CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virus-infected patients in South India. Antimicrob. Agents Chemother. 53:863-868.
14. Rotger, M., C. Csajka, and A. Telenti. 2006. Genetic, ethnic, and gender differences in the pharmacokinetics of antiretroviral agents. Curr. HIV/ AIDS Rep. 3:118-125.
15. Rotger, M., H. Tegude, S. Colombo, M. Cavassini, H. Furrer, L. Decosterd, J. Blievernicht, T. Saussele, H. F. Gunthard, M. Schwab, M. Eichelbaum, A. Telenti, and U. M. Zanger. 2007. Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clin. Pharmacol. Ther. 81:557-566.
16. Stöhr, W., D. Back, D. Dunn, C. Sabin, A. Winston, R. Gilson, D. Pillay, T. Hill, J. Ainsworth, A. Pozniak, C. Leen, L. Bansi, M. Fisher, C. Orkin, J. Anderson, M. Johnson, P. Easterbrook, S. Gibbons, and S. Khoo. 2008. Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication. Antivir. Ther. 13:675-685.
17. Veldkamp, A. I., G. J. Weverling, J. M. Lange, J. S. Montaner, P. Reiss, D. A. Cooper, S. Vella, D. Hall, J. H. Beijnen, and R. M. Hoetelmans. 2001. High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS 15:1089-1095.